These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21147904)

  • 1. Biologics in cervical cancer therapy.
    Willmott LJ; Sumner DA; Monk BJ
    J Natl Compr Canc Netw; 2010 Dec; 8(12):1417-23. PubMed ID: 21147904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
    Willmott LJ; Monk BJ
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeted therapy in locally and metastatic recurrent cervical cancers].
    Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
    Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of metastatic cervical cancer: future directions involving targeted agents.
    Diaz-Padilla I; Monk BJ; Mackay HJ; Oaknin A
    Crit Rev Oncol Hematol; 2013 Mar; 85(3):303-14. PubMed ID: 22883215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and targeted therapy in the management of cervical cancer.
    Kumar L; Harish P; Malik PS; Khurana S
    Curr Probl Cancer; 2018; 42(2):120-128. PubMed ID: 29530393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN; Tewari KS
    Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.
    Monk BJ; Tewari KS; Koh WJ
    J Clin Oncol; 2007 Jul; 25(20):2952-65. PubMed ID: 17617527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy in cervical cancer patients with high risk factors.
    Park TK
    Yonsei Med J; 1997 Oct; 38(5):255-60. PubMed ID: 9409188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in lung cancer: clinical developments and future directions.
    Blumenschein G
    J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S124-7. PubMed ID: 18520294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy.
    Rossi A; Maione P; Sacco PC; Ambrosio R; Falanga M; Gridelli C
    Curr Drug Targets; 2010 Jul; 11(7):865-8784. PubMed ID: 20412044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
    Kumar L; Gupta S
    Oncology; 2016; 91 Suppl 1():8-17. PubMed ID: 27464068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
    Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
    Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.
    Lheureux S; Oza AM
    Eur J Cancer; 2016 May; 59():99-108. PubMed ID: 27017291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
    Tewari KS; Monk BJ
    Clin Cancer Res; 2014 Nov; 20(21):5349-58. PubMed ID: 25104084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
    Tewari KS; Monk BJ
    Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenesis, anti-VEGF(R) and outlook.
    Petersen I
    Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locally advanced cervical cancer: what is the standard of care?
    Al-Mansour Z; Verschraegen C
    Curr Opin Oncol; 2010 Sep; 22(5):503-12. PubMed ID: 20473164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.